DOOR stock was delisted from NYSE on
May 14, 2024. You can explore more stocks from
Industrials sector on this page.
OVID Ovid Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: OVID
Price (delayed)
$0.294
Market cap
$20.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
$7.42M
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these
Highlights
Ovid Therapeutics's debt has shrunk by 68% YoY and by 8% QoQ
The EPS is up by 49% YoY and by 20% QoQ
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
The gross profit has grown by 44% YoY but it has contracted by 10% from the previous quarter
OVID's quick ratio is down by 44% YoY and by 6% QoQ
OVID's equity is down by 22% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of OVID
Market
Valuations
Earnings
Shares outstanding
71.08M
Market cap
$20.9M
Enterprise value
$7.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
36.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.11
Revenue
$566,000
Gross profit
$566,000
Operating income
-$61.89M
Net income
-$26.43M
EBIT
-$26.43M
EBITDA
-$24.72M
Free cash flow
-$56.03M
Per share
Balance sheet
Liquidity
EPS
-$0.37
EPS diluted
-$0.37
Free cash flow per share
-$0.79
Book value per share
$0.96
Revenue per share
$0.01
TBVPS
$1.3
Total assets
$92.17M
Total liabilities
$23.94M
Debt
$14.76M
Equity
$68.23M
Working capital
$45.42M
Debt to equity
0.22
Current ratio
5.32
Quick ratio
5.23
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
-4,368%
Gross margin
100%
Net margin
-4,670.1%
Operating margin
-10,933.7%
Return on assets
-23.8%
Return on equity
-33.9%
Return on invested capital
-27.6%
Return on capital employed
-32.4%
Return on sales
-4,670.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OVID stock price
How has the Ovid Therapeutics stock price performed over time
Intraday
-1.28%
1 week
-6.73%
1 month
15.29%
1 year
-90.49%
YTD
-68.51%
QTD
-5.74%
Financial performance
How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$566,000
Gross profit
$566,000
Operating income
-$61.89M
Net income
-$26.43M
Gross margin
100%
Net margin
-4,670.1%
Ovid Therapeutics's net margin has surged by 65% YoY and by 9% QoQ
The net income has grown by 49% YoY and by 19% from the previous quarter
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
The gross profit has grown by 44% YoY but it has contracted by 10% from the previous quarter
Price vs fundamentals
How does OVID's price correlate with its fundamentals
Growth
What is Ovid Therapeutics's growth rate over time
Valuation
What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.31
P/S
36.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.11
The EPS is up by 49% YoY and by 20% QoQ
OVID's price to book (P/B) is 87% less than its 5-year quarterly average of 2.4 and 78% less than its last 4 quarters average of 1.4
OVID's equity is down by 22% YoY and by 11% from the previous quarter
OVID's price to sales (P/S) is 88% less than its 5-year quarterly average of 301.9 and 82% less than its last 4 quarters average of 200.1
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
Efficiency
How efficient is Ovid Therapeutics business performance
The ROS has soared by 65% YoY and by 9% QoQ
OVID's ROIC is up by 50% YoY
The return on assets has increased by 38% year-on-year and by 9% since the previous quarter
Ovid Therapeutics's ROE has increased by 32% YoY and by 14% from the previous quarter
Dividends
What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OVID.
Financial health
How did Ovid Therapeutics financials performed over time
The total liabilities has plunged by 57% YoY and by 9% from the previous quarter
The company's current ratio fell by 44% YoY and by 6% QoQ
Ovid Therapeutics's debt is 78% lower than its equity
Ovid Therapeutics's debt has shrunk by 68% YoY and by 8% QoQ
Ovid Therapeutics's debt to equity has plunged by 58% YoY but it has increased by 4.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.